Researchers identified DNA methylation markers that may indicate the risk of developing schizophrenia later in life in newborns. This breakthrough discovery could allow for early detection and intervention to reduce the impact of the disease. By studying blood samples collected at birth, the team was able to identify unique methylation differences in cell types that could become potential clinical biomarkers for future early detection of schizophrenia.
